12/05/2025 – AB Science reports its revenues for the year 2024 and provides an update on its activities Download PDF Post navigationPreviousPrevious post:AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingNextNext post:CNews – Interview of Alain MoussyRelated PostsAB Science announces the successful completion of a EUR 1.925 million private placementJuly 8, 2025Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025
Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025
New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025